In the advanced-stage model, the pronounced effects of the JX-594 and PD-1 inhibitor combination were reduced compared with the ICI combination, with no significant differences between the groups in primary tumor reduction or the number of lung nodules (Fig. 2B and 2D). Here, PDCD1 is linked to neoplasm.